Shares of Trovagene Inc. (NASDAQ:TROV) fell 2.7% during mid-day trading on Friday . The company traded as low as $5.48 and last traded at $5.49, with a volume of 163,092 shares traded. The stock had previously closed at $5.64.

A number of research firms have recently issued reports on TROV. Cantor Fitzgerald lowered shares of Trovagene from a “buy” rating to a “hold” rating and reduced their price target for the stock from $9.00 to $5.00 in a research report on Monday, April 25th. Piper Jaffray Cos. lowered shares of Trovagene from an “overweight” rating to a “neutral” rating and increased their price target for the stock from $5.26 to $8.00 in a research report on Monday, April 25th. Maxim Group increased their price target on shares of Trovagene from $9.00 to $12.00 and gave the stock a “buy” rating in a research report on Friday, August 5th. Zacks Investment Research raised shares of Trovagene from a “sell” rating to a “hold” rating in a research report on Wednesday, July 13th. Finally, Leerink Swann lowered shares of Trovagene from an “outperform” rating to a “sector perform” rating in a research report on Tuesday, April 26th. Six research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $7.13.

The stock’s market cap is $165.81 million. The company’s 50-day moving average price is $5.24 and its 200-day moving average price is $4.96.

Trovagene (NASDAQ:TROV) last posted its earnings results on Thursday, August 4th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.31) by $0.03. On average, equities research analysts forecast that Trovagene Inc. will post ($1.33) EPS for the current year.

Trovagene, Inc (TrovaGene) is a molecular diagnostic company. The Company focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. Its primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.